Keywords: |
unclassified drug; cancer risk; note; cancer staging; outcome assessment; sensitivity and specificity; prostate specific antigen; protein degradation; tumor markers, biological; editorial; proteomics; tumor marker; prediction; risk assessment; risk; prostatic neoplasms; molecular marker; blood; prostate tumor; measurement; kallikrein; prediction and forecasting; predictive value of tests; proteinase; matrix assisted laser desorption ionization time of flight mass spectrometry; plasminogen activator inhibitor 1; plasma protein; urokinase; cell surface receptor; receptors, cell surface; trypsin; urokinase receptor; plasmin; peptidomics; plasminogen activator inhibitor 2; plasminogen activator inhibitor 3; plasminogen activator, urokinase receptors; blood component; urinary plasminogen activator
|